

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PREScriBER

Name: Name:

Ward: NHI:

Trastuzumab (Herzuma)

INITIATION – early breast cancer

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

The patient has early breast cancer expressing HER-2 IHC 3+ or ISH + (including FISH or other current technology)
and
 Maximum cumulative dose of 106 mg/kg (12 months' treatment)

CONTINUATION – early breast cancer*

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology)
and
 The patient received prior adjuvant trastuzumab treatment for early breast cancer
and
 The patient has not previously received lapatinib treatment for HER-2 positive metastatic breast cancer
or
 The patient discontinued lapatinib within 3 months due to intolerable side effects and the cancer did not progress whilst on lapatinib
or
 The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab
and
 Trastuzumab will not be given in combination with pertuzumab
or
 Trastuzumab to be administered in combination with pertuzumab
and
 Patient has not received prior treatment for their metastatic disease and has had a treatment-free interval of at least 12 months between prior (neo)adjuvant chemotherapy treatment and diagnosis of metastatic breast cancer
and
 The patient has good performance status (ECOG grade 0-1)
and
 Trastuzumab to be discontinued at disease progression
or
 Patient has previously discontinued treatment with trastuzumab in the metastatic setting for reasons other than severe toxicity or disease progression
and
 Patient has signs of disease progression
and
 Disease has not progressed during previous treatment with trastuzumab

Note: * For patients with relapsed HER-2 positive disease who have previously received adjuvant trastuzumab for early breast cancer

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PREScriBER

Name: Name:

Ward: NHI:

Trastuzumab (Herzuma) - continued

INITIATION – metastatic breast cancer

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology)
and
 - The patient has not previously received lapatinib treatment for HER-2 positive metastatic breast cancer
 - or**
 - The patient discontinued lapatinib within 3 months due to intolerable side effects and the cancer did not progress whilst on lapatinib
- and**
 - Trastuzumab will not be given in combination with pertuzumab
 - or**
 - Trastuzumab to be administered in combination with pertuzumab
 - and**
 - Patient has not received prior treatment for their metastatic disease and has had a treatment-free interval of at least 12 months between prior (neo)adjuvant chemotherapy treatment and diagnosis of metastatic breast cancer
 - and**
 - The patient has good performance status (ECOG grade 0-1)
- and**
 - Trastuzumab to be discontinued at disease progression

CONTINUATION – metastatic breast cancer

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- and**
 - The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology)
 - The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab
 - Trastuzumab to be discontinued at disease progression
- or**
 - Patient has previously discontinued treatment with trastuzumab for reasons other than severe toxicity or disease progression
 - and**
 - Patient has signs of disease progression
 - and**
 - Disease has not progressed during previous treatment with trastuzumab

INITIATION – gastric, gastro-oesophageal junction and oesophageal cancer

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- and**
 - The patient has locally advanced or metastatic gastric, gastro-oesophageal junction or oesophageal cancer expressing HER-2 IHC 2+ FISH+ or IHC3+ (or other current technology)
 - Patient has an ECOG score of 0-2

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PREScriBER

Name:

Ward: NHI:

Trastuzumab (Herzuma) - *continued*

CONTINUATION – gastric, gastro-oesophageal junction and oesophageal cancer

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab
and
 Trastuzumab to be discontinued at disease progression

I confirm that the above details are correct:

Signed: Date: